We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+30.64%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.06B
AUM Growth
+$264M
Cap. Flow
+$103M
Cap. Flow %
9.71%
Top 10 Hldgs %
50.25%
Holding
118
New
40
Increased
18
Reduced
23
Closed
31

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$50.2M
2
NICE icon
Nice
NICE
+$22.7M
3
AMGN icon
Amgen
AMGN
+$18.3M
4
AZN icon
AstraZeneca
AZN
+$16.5M
5
LLY icon
Eli Lilly
LLY
+$13.8M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$22.4M
2
PFE icon
Pfizer
PFE
+$19.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$18.3M
4
NVO
Novo Nordisk
NVO
+$11.2M
5
XLP icon
State Street Consumer Staples Select Sector SPDR ETF
XLP
+$7.91M

Sector Composition

Rank Sector Weight
1 Healthcare 64.11%
2 Technology 8.21%
3 Consumer Discretionary 1.63%
4 Industrials 1.41%
5 Communication Services 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$84M 7.9%
750,000
+250,000
+50% +$24.6M
ABBV icon
2
AbbVie
ABBV
$443B
$72.1M 6.78%
734,598
+569,598
+345% +$50.2M
MRK icon
3
Merck
MRK
$322B
$60.6M 5.7%
821,431
-88,776
-10% -$6.68M
SPY icon
4
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$58.3M 5.48%
189,000
-20,900
-10% -$6.12M
SNY icon
5
Sanofi
SNY
$103B
$57.2M 5.38%
1,120,000
+150,000
+15% +$7.29M
AZN icon
6
AstraZeneca
AZN
$263B
$47.1M 4.43%
445,000
+160,000
+56% +$16.5M
JNJ icon
7
Johnson & Johnson
JNJ
$618B
$42.2M 3.97%
300,000
-48,653
-14% -$7.09M
BMY icon
8
Bristol-Myers Squibb
BMY
$133B
$41.2M 3.87%
700,000
-80,000
-10% -$4.79M
QQQ icon
9
PUT
Invesco QQQ Trust
QQQ
$453B
$39M 3.67%
+157,500
New +$35.3M
PFE icon
10
PUT
Pfizer
PFE
$143B
$32.7M 3.08%
+1,054,000
New +$35.8M
NVO
11
Novo Nordisk
NVO
$208B
$26.2M 2.46%
800,000
-352,000
-31% -$11.2M
FOLD
12
DELISTED
Amicus Therapeutics
FOLD
$24.6M 2.31%
1,628,550
-389,074
-19% -$4.74M
NICE icon
13
Nice
NICE
$5.79B
$24.5M 2.3%
+129,406
New +$22.7M
SRPT icon
14
Sarepta Therapeutics
SRPT
$1.57B
$19.8M 1.86%
123,200
-134,800
-52% -$18.3M
AMGN icon
15
Amgen
AMGN
$208B
$18.9M 1.77%
+80,000
New +$18.3M
DCPH
16
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$16.9M 1.59%
282,965
+163,465
+137% +$8.74M
MSFT icon
17
Microsoft
MSFT
$3.45T
$16.7M 1.57%
81,964
-12,000
-13% -$2.18M
NVS icon
18
Novartis
NVS
$297B
$15.7M 1.48%
180,000
+40,000
+29% +$3.45M
LLY icon
19
Eli Lilly
LLY
$1.02T
$14.8M 1.39%
+90,000
New +$13.8M
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$12.8M 1.2%
+82,049
New +$12.5M
FVRR icon
21
Fiverr
FVRR
$321M
$12.3M 1.16%
167,002
+62,163
+59% +$3.19M
YMAB
22
DELISTED
Y-mAbs Therapeutics
YMAB
$12.2M 1.15%
282,252
-25,127
-8% -$950K
AMZN icon
23
Amazon
AMZN
$2.92T
$11.9M 1.12%
86,400
-19,000
-18% -$2.29M
ALLT icon
24
Allot
ALLT
$372M
$10.1M 0.95%
963,456
+48,154
+5% +$511K
QTTB icon
25
Q32 Bio
QTTB
$466M
$10M 0.94%
+36,607
New +$9.76M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sphera Funds Management held 118 positions worth $1.06B, up 33% from $800M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sphera Funds Management deployed $103M of net new capital in Q2 2020, opening 40 new positions and adding to 18 existing holdings. Its largest new stake was Nice: 129,406 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 66% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $18.3M trimmed.

  • Sphera Funds Management's largest Q2 2020 buy was Nice: 129,406 shares worth $24.5M.
  • Sphera Funds Management added most to AbbVie in Q2 2020, an estimated $50.2M increase.
  • Sphera Funds Management's biggest Q2 2020 reduction was Sarepta Therapeutics, cutting an estimated $18.3M.
  • Sphera Funds Management fully exited Alexion Pharmaceuticals in Q2 2020, selling an estimated $22.4M.
  • Sphera Funds Management's ten largest holdings make up 50% of its $1.06B portfolio in Q2 2020.
  • Sphera Funds Management opened 40 new positions and closed 31 in Q2 2020.
  • Sphera Funds Management's portfolio value rose 33% quarter-over-quarter to $1.06B.

Based on Sphera Funds Management's 13F filing for Q2 2020, filed 13 Aug 2020.